Table 1.

Correlation Between Peripheral NLR, PLR, MLR, and Clinical Variables of HCC Patients

Variables	Cases	NLR		P	PLR		P	MLR		P
		<3.82	≥3.82		<140.00	≥140.00		<0.27	≥0.27
Gender
Male	348	237	111		265	83		158	190
Female	59	37	22	0.414	44	15	0.794	24	35	0.500
Age
<60	236	162	74		184	52		114	122
≥60	171	112	59	0.504	125	46	0.257	68	103	0.087
T stage
I	46	37	9		37	9		24	22
II	117	90	27		100	17		61	56
III	229	139	90		161	68		90	139
IV	15	8	7	0.002	11	4	0.012	7	8	0.091
N stage
0	294	203	91		228	66		142	152
I	113	71	42	0.231	81	32	0.215	40	73	0.019
M stage
0	364	252	112		281	83		170	194
I	43	22	21	0.017	28	15	0.080	12	31	0.019
BCLC staging
A	131	101	30		109	22		69	62
B	131	83	48		99	32		65	66
C	143	90	53		99	44		48	95
D	2	0	2	0.005	2	0	0.045	0	2	0.002
LDH
<199.00	160	127	33		137	23		90	70
≥199.00	247	147	100	<0.001	172	75	<0.001	92	155	<0.001
ALP
<134.50	239	178	61		204	35		130	109
≥134.50	168	96	72	<0.001	105	63	<0.001	52	116	<0.001
CEA
<7.93	372	256	116		281	91		174	198
≥7.93	35	18	17	0.036	28	7	0.555	8	27	0.007
Hepatitis
Without hepatitis	181	120	61		135	46		83	98
Hepatitis B	209	142	67		160	49		93	116
Hepatitis C	6	4	2	0.916	5	1	0.899	1	5	0.403
Liver cirrhosis
No	183	123	60		131	52		85	98
Yes	209	144	65	0.721	169	40	0.031	93	116	0.699
Portal vein involvement
Yes	68	48	20		49	19		26	42
No	310	208	102	0.577	237	73	0.445	142	168	0.255
Surgical history
Yes	177	122	55	0.545	138	39	0.397	88	89
No	230	152	78		171	59		95	135	0.091
Interventional
Treatment
TACE	223	141	82		168	55		93	130
TAI	180	132	48	0.019	138	42	0.952	89	91
TAE	4	1	3		3	1		1	3	0.216
AFP
<400	241	166	75	0.615	200	41	<0.001	114	127
≥400	152	101	51		101	51		65	87	0.379

Abbreviations: NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; MLR, monocyte–lymphocyte ratio; BCLC staging, Barcelona Clinic Liver Cancer staging; LDH, lactate dehydrogenase; ALP,alkaline phosphatase; CEA, carcinoembryonic antigen; AFP, α-fetoprotein. P-values in bold were found to be significant.